BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17143501)

  • 1. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer.
    Iniesta P; Morán A; De Juan C; Gómez A; Hernando F; García-Aranda C; Frías C; Díaz-López A; Rodríguez-Jiménez FJ; Balibrea JL; Benito M
    Oncol Rep; 2007 Jan; 17(1):217-23. PubMed ID: 17143501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.
    Morán A; Iniesta P; García-Aranda C; De Juan C; Díaz-López A; Sánchez-Pernaute A; Torres AJ; Díaz-Rubio E; Balibrea JL; Benito M
    Oncol Rep; 2005 Jan; 13(1):115-20. PubMed ID: 15583811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
    Wei QY; Wu YQ; Fan SQ
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
    Safranek J; Pesta M; Holubec L; Kulda V; Dreslerova J; Vrzalova J; Topolcan O; Pesek M; Finek J; Treska V
    Anticancer Res; 2009 Jul; 29(7):2513-7. PubMed ID: 19596921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
    Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
    Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
    Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
    Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer.
    Mino N; Takenaka K; Sonobe M; Miyahara R; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Mar; 95(3):250-7. PubMed ID: 17323339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR.
    Simi L; Andreani M; Davini F; Janni A; Pazzagli M; Serio M; Orlando C
    Lung Cancer; 2004 Aug; 45(2):171-9. PubMed ID: 15246188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
    Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y
    Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer.
    Aljada IS; Ramnath N; Donohue K; Harvey S; Brooks JJ; Wiseman SM; Khoury T; Loewen G; Slocum HK; Anderson TM; Bepler G; Tan D
    J Clin Oncol; 2004 Aug; 22(16):3218-29. PubMed ID: 15249585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancer.
    Safranek J; Holubec L; Topolcan O; Pesta M; Klecka J; Vodicka J; Finek J; Kormunda S; Pesek M
    Anticancer Res; 2007; 27(4C):2953-6. PubMed ID: 17695477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer.
    Thomas P; Khokha R; Shepherd FA; Feld R; Tsao MS
    J Pathol; 2000 Feb; 190(2):150-6. PubMed ID: 10657012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
    Baker EA; Bergin FG; Leaper DJ
    Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer.
    Suemitsu R; Yoshino I; Tomiyasu M; Fukuyama S; Okamoto T; Maehara Y
    Surg Today; 2004; 34(11):896-901. PubMed ID: 15526122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
    Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
    J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
    Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
    Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
    Pennanen H; Kuittinen O; Turpeenniemi-Hujanen T
    Eur J Haematol; 2008 Jan; 80(1):46-54. PubMed ID: 18028436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.